Pluri Inc.
$ 2.25
0.00%
17 Jun - close price
- Market Cap 24,276,500 USD
- Current Price $ 2.25
- High / Low $ 2.27 / 2.25
- Stock P/E N/A
- Book Value -1.78
- EPS -2.90
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.51 %
- ROE -10.22 %
- 52 Week High 5.96
- 52 Week Low 2.22
About
Pluri Inc. is a pioneering biotechnology company focused on regenerative medicine and immunotherapy, leveraging its proprietary technology platform to create cutting-edge cell-based therapies targeting oncology and degenerative diseases. Dedicated to addressing significant unmet medical needs, Pluri is expanding its pipeline of innovative therapeutics while forging strategic collaborations that enhance its capability to improve patient outcomes. With its commitment to advancing healthcare solutions, Pluri is poised to emerge as a key player in the biotech sector, driving growth and delivering meaningful advancements in patient care.
Analyst Target Price
$12.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-09-17 | 2025-05-13 | 2025-02-11 | 2024-11-12 | 2024-09-18 | 2024-05-09 | 2024-02-12 | 2023-11-13 | 2023-09-12 | 2023-05-09 | 2023-02-13 |
| Reported EPS | -0.65 | -1 | -0.9365 | -0.5323 | -1.0774 | -1.0593 | -1.0138 | -0.1181 | -0.19 | -0.16 | -0.19 | -1.92 |
| Estimated EPS | -0.74 | -0.73 | None | None | None | None | None | -0.32 | -0.32 | -0.31 | -0.3 | -2.56 |
| Surprise | 0.09 | -0.27 | 0 | 0 | 0 | 0 | 0 | 0.2019 | 0.13 | 0.15 | 0.11 | 0.64 |
| Surprise Percentage | 12.1622% | -36.9863% | None% | None% | None% | None% | None% | 63.0938% | 40.625% | 48.3871% | 36.6667% | 25% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLUR
2026-06-11 08:39:59
This article provides a detailed overview of Pluri Inc. (NASDAQ:PLUR) stock, including its current price, historical performance, earnings information, and key financial stats. It also offers technical analysis summaries, lists ETFs holding the stock, and answers frequently asked questions about the company's financial health and stock behavior.
2026-06-05 20:09:40
Pluri's subsidiary Cellav has completed the listing of its regenerative aesthetic products with the FDA, moving closer to a commercial launch in the U.S. This development enables Cellav to market its products in the U.S. and represents a significant step for Pluri in expanding its presence in the medical aesthetics market. The company anticipates a Q4 2026 launch in the U.S. for its new portfolio of solutions.
2026-06-03 06:09:25
Pluri Inc.'s subsidiary, Cellav Health and Aesthetics Ltd., has completed the U.S. cosmetic product listing for two regenerative aesthetic products, Regenativo+ and Placento+. This clears the path for their commercial launch in the U.S. market, which is projected to reach $90 billion by 2030. Cellav is now in discussions with distributors and strategic partners to capitalize on the rapidly growing medical aesthetics sector.
2026-06-02 19:43:00
Pluri Inc., through its subsidiary Cellav, has completed the cosmetic product listings for two regenerative aesthetic products, Regenativo+ and Placento+, in the U.S. This development paves the way for their commercial launch in the U.S. market in 2026, targeting the rapidly growing medical aesthetics sector. Cellav is actively pursuing partnerships and distributors to establish a strong commercial presence for these clinically validated, scalable products.
2026-06-02 16:39:29
Israeli biotech firm Pluri Inc., through its subsidiary Cellav Health and Aesthetics, has secured U.S. cosmetic product listings for Regenativo+ and Placento+, setting the stage for a 2026 launch into the medical aesthetics market. This move represents a strategic pivot for Pluri from R&D to commercialization, leveraging its cell-expansion platform to target the high-margin regenerative beauty sector. While offering a faster route to revenue within cosmetic regulations, success is crucial for Pluri, given its current financial challenges and broader aspirations in the longevity sector.
2026-06-02 11:40:57
Pluri's subsidiary, Cellav, has completed U.S. cosmetic listings for two regenerative aesthetic products, Regenativo+ and Placento+, paving the way for a 2026 commercial launch in the U.S. These clinically validated formulations target the rapidly growing U.S. medical aesthetics market, projected to reach $90 billion by 2030, and have shown significant improvements in various skin parameters in studies. Cellav is now actively engaging with distributors and strategic partners to secure initial commercial orders and build a scalable commercial platform.
